LoginRegister
    AstraZeneca cancer drug Imfinzi gets USFDA priority reviewAstraZeneca cancer drug Imfinzi gets USFDA priority review
    Cipla shares jump 2 pc post agreement with CitiHealth ImportsCipla shares jump 2 pc post agreement with CitiHealth Imports
    NATHEALTH would like to make India as healthcare destination of the world: Sudarshan BallalNATHEALTH would like to make India as healthcare destination of the world: Sudarshan Ballal
    Medtronic drug-coated balloon IN.PACT AV gets USFDA nod to treat AV FistulaesMedtronic drug-coated balloon IN.PACT AV gets USFDA nod to treat AV Fistulaes
    Surgical Traders and Manufacturers oppose classification of popular devices as Drugs, write to Health MinisterSurgical Traders and Manufacturers oppose classification of popular devices as Drugs, write to...
    Novartis USD 90 million gene, cell therapy factory to begin Kymriah, Zolgensma production in 2020Novartis USD 90 million gene, cell therapy factory to begin Kymriah, Zolgensma production in 2020
    Drugmakers including Novartis, Roche slash prices by 61pc in China to get on reimbursement listDrugmakers including Novartis, Roche slash prices by 61pc in China to get on reimbursement list
    ImmuPharma, Avion sign licensing agreement for lupus drug Lupuzor in USImmuPharma, Avion sign licensing agreement for lupus drug Lupuzor in US
    UP Govt orders pull back of substandard Atorvastatin medicine from govt hospitalsUP Govt orders pull back of substandard Atorvastatin medicine from govt hospitals
    Cipla arm to acquire remaining 40 pc stake in Cipla Pharma Lanka for over Rs 1.5 lakhCipla arm to acquire remaining 40 pc stake in Cipla Pharma Lanka for over Rs 1.5 lakh
    Biocon, Mylan get USFDA nod for pegfilgrastim from new Bengaluru facilityBiocon, Mylan get USFDA nod for pegfilgrastim from new Bengaluru facility
    Centaur Pharma Ambernath facility receives EIR from USFDACentaur Pharma Ambernath facility receives EIR from USFDA
    Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

    Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

    © 2025 - Medical Dialogues. All Rights Reserved.
    Powered By: Hocalwire
    X